CG Oncology: 'Strong Buy' On Earlier Than Expected Completed Recruitment Cretostimogene

2026-01-11 08:30:11 ET

The last time I spoke about CG Oncology ( CGON ) it was with respect to a Seeking Alpha article entitled " CG Oncology: Positive Phase 3 Outcome Could Lead To BLA Of Cretostimogene ". With respect to this article, I noted that the company had achieved positive results from Cohort C of its phase 3 BOND-003 study using its drug cretostimogene as a monotherapy to treat patients with high-risk BCG-unresponsive non-muscle invasive bladder cancer [NMIBC]. As an update for this program, I want to state that the company provided an update back in November of 2025 that it initiated the rolling Biologics License Application [BLA] of this therapy to treat these particular NMIBC patients. Since my last article on this biotech, the stock has gained 88.46% because of the progress it has made. Plus, I had given this stock a "Strong Buy" rating as well. I believe it is important to maintain this rating because it has a solid pipeline. But, if the BLA was already submitted, then what catalysts could be left for shareholders to consider? Ones that could possibly cause the stock price to trade higher? Even though the BLA of cretostimogene was already filed for high-risk BCG-unresponsive NMIBC patients, the rolling submission hasn't been completed....

Read the full article on Seeking Alpha

For further details see: